• November 29, 

1978
Biocon’s Founding Day - the start of a
biorevolution in India. Over the years, Biocon has
evolved from an enzyme-manufacturing company
into a fully integrated biopharmaceutical
enterprise. Today, we leverage a formidable
combination of proprietary fermentation
technologies and research skills to develop
affordable therapy for unmet medical needs 
Biocon India is incorporated as a joint venture
between Biocon Biochemicals Ltd. of Ireland and
an Indian entrepreneur, Kiran Mazumdar-Shaw 
• Biocon is a research-driven, global healthcare
company with a strong matrix of capabilities
along the biopharmaceutical value chain.
Focusing on unmet medical needs in cancer,
diabetes and inflammatory diseases, we offer
novel therapies on a platform of affordable
innovation.
• We believe our strategic licensing partnerships
will rapidly provide us wider global access and
greater market penetration. More significantly,
they will enable us to deliver breakthrough
therapeutics to millions of patients the world
over.
 Located in Bangalore, India, Biocon has two
subsidiaries, Syngene, a custom research
organization, and Clinigene, a clinical
research organization.
Chairman & Managing Director Founder
  Entrepreneur, 1978
 Dr. Neville Bain
Chairman, Institute of Directors, UK 
 Biocon’s cardiology, nephrology, diabetology
and oncology products including BESTOR®,
BASALOGTM, BioMAb EGFR®, STATIX®, NUFIL
safeTM, INSUGEN®, TACROGRAFTM, ERYPRO
safeTM, and MYOKINASETM are considerably
less expensive than other leading brands.
 In 2009-10, Biocon’s net income increased
44% to Rs. 24,048 million, crossing the half-
billion-dollar mark and profits grew 215% to
Rs. 2,933 million. The pharmaceutical
business exceeded Rs. 200,871 million in
revenue and the net R&D expenditure
increased to Rs. 917 million, growing 42%
over 2008 and up 282% over 2005, while its
research services business crossed Rs. 2,807
million.